Jul. 28 at 4:26 AM
$TNFA
TNFA
– Set up like past low-float biotech runners 📈
✅ Float: ~13M – ultra tight like
$SBFM,
$INM,
$IXHL before their runs
✅ Institutional confidence: Morgan Stanley increased position 61% in Q1 2025 (holds 3.7%)
✅ Imminent Phase 2b data – Isomyosamine trial started Feb, 150+ days passed
✅ Warrant wall at
$0.364 – could be incentive to push above and raise capital
✅ Oversold bounce + reclaim of 50DMA + falling wedge breakout
✅ High short interest + retail starting to notice
🧠 Similar past plays:
•
$SBFM – Ran from
$0.22 to
$1.60 on cancer data
•
$INM – <
$0.20 to
$0.95 after clean Phase 2 and short squeeze
•
$IXHL – Quiet under
$0.30, exploded past
$1+ on trial news
🎯 TNFA Price Targets:
• Base case:
$0.50–
$0.80
• Squeeze/FOMO:
$1+ like
$IXHL
This is one to keep eyes on. Microcap biotech, huge upside, real catalyst window NOW.
$TNFA
